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We studied in 32 patients on maintenance hemodialysis (duration of
treatment 6 to 133 months) whether duration of dialysis treatment
affects blood pressure, plasma noradrenaline levels and a2-adrenoce-
ptor density (assessed in platelet membranes by 3H-yohimbine binding).
Plasma noradrenaline levels were a significant inverse correlation to
platelet a2-adrenoceptor density. In addition, mean arterial blood—pres-
sure, plasma noradrenaline levels and platelet a2-adrenoceptor density
were significantly related to the duration of treatment: with increasing
duration of treatment plasma noradrenaline levels increased, whereas
mean arterial blood—pressure and platelet a2-adrenoceptor density de-
creased. Furthermore, changes in mean arterial blood—pressure were
inversely related to plasma noradrenaline levels and positively to
platelet a2-adrenoceptor density. Platelet cs2-adrenoceptor changes
were accompanied by similar alterations in (vascular) a,-adrenoceptor
responsiveness (assessed by blood pressure responses to i.v. injections
of phenylephrine); in hypotensive hemodialysis patients, who had high,
plasma noradrenaline levels and low, platelet a2-adrenoceptor density,
the dose of phenylephrine necessary to increase systolic blood pressure
by 20 mm Hg was nearly twice as high as in normotensive dialysis
patients and healthy controls. In autonomic tests, Valsalva—ratio was
lower in hypotensive than in normotensive dialysis patients and healthy
controls, whereas no differences were found in blood pressure and heart
rate responses during sustained hand—grip exercise as well as in beat—
to—beat variation during deep breathing. It is concluded that with
increasing duration of the dialysis treatment, pathological changes in
mean arterial blood—pressure, plasma noradrenaline levels and platelet
a2-adrenoceptor density increase; moreover, in the course of long—term
treatment, baroreceptor dysfunction develops obviously due to a defect
in the afferent limb of the barorefiex arc. The (possibly to this barore-
ceptor dysfunction refiectorily) increased plasma noradrenaline levels
may induce a-adrenoceptor down—regulation. The resulting reduction
in a-adrenoceptor responsiveness to a-adrenergic stimuli (including
endogenous catecholamines) might be one important cause of arterial
hypotension in patients on long—term hemodialysis treatment.
Abnormalities of autonomic control of the cardiovascular
system have been frequently observed in patients with chronic
renal insufficiency undergoing hemodialysis [1. 21. Reduced
baroreceptor sensitivity [3], abnormal responses to the Valsalva
maneuver [4], dialysis—induced hypotension [5, 6] and elevated
plasma noradrenaline levels [7—9] have been reported. In addi-
tion, blood pressure response to noradrenaline infusion was
found to be markedly attenuated in patients on maintenance
hemodialysis, suggesting an impaired (vascular) a-adrenoceptor
function [51. In animal models of experimental chronic uremia
an attenuated a-adrenoceptor responsiveness (assessed as vas-
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cular response to noradrenaline infusion of the isolated, per-
fused rat hind limb) has as well been observed [10] and a
decreased vascular a-adrenoceptor density was reported [11].
However, little is known on changes in the properties of
a-adrenoceptors—the targets of catecholamines—in patients on
maintenance hemodialysis. In the present study, we therefore
determined the density of cs2-adrenoceptors in circulating plate-
lets (by 3H-yohimbine binding) and the responsiveness of
(vascular) a1-adrenoceptors (by blood pressure responses to
i.v. injections of the selective a-adrenoceptor agonist phenyl-
ephrine) in 32 hemodialysis patients with a different duration of
treatment (6 to 133 months) in order to find out whether in the
course of long—term dialysis treatment similar changes in a-
adrenoceptor function might occur as in experimental chronic
uremia. In addition we determined plasma noradrenaline levels
and studied autonomic function by three standardized cardio-
vascular autonomic tests (Valsalva—maneuver, sustained hand-
grip exercise, and beat—to—beat variation during deep breathing)
to evaluate whether the increase in plasma noradrenaline levels
observed in patients on chronic hemodialysis treatment might
be cause or consequence of possible changes in a-adrenoceptor
function.
Methods
Thirty—two patients on maintenance hemodialysis (24 males,
8 females; mean age 48.5 2.1 [24 to 69] years; duration of
hemodialysis treatment 6 to 133 months) participated in the
study after having given informed written consent. The causes
of renal failure in the 32 patients were chronic glomerulonephri-
tis in 15, polycystic kidney disease in 6, nephropathy due to
analgesic drugs in 3, chronic pyelonephritis in 3, cortical
necrosis in 1 and chronic renal failure of uncertain etiology in 4
patients. The development of interdialytic blood pressure of the
patients in relation to blood pressure levels before initiation of
dialysis treatment and duration of dialysis treatment is given in
Table 1. All patients were not on antihypertensive therapy for at
least three weeks. Medication consisted of calcium carbonate,
sodium hydrogencarbonate, aluminium containing phosphate
binding drugs, l-alpha-hydroxyvitamin D3, multivitamins and
iron supplementation. Hemodialysis treatment was performed
three times, five to six hours per week as standard acetate
dialysis with additional infusion of sodium bicarbonate [12].
After 30 minutes of rest, blood pressure was measured by the
auscultatory method (diastolic phase V) with the patients in
sitting position. Blood pressure values are given as average of at
least three measurements on separate days. Blood pressure was
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Table 1. Development of blood pressure in 32 patients on maintenance hemodialysis in relation to blood p
dialysis treatment and duration of dialysis treatment
ressure levels before initiation of
Patients
After I year of dialysis After I to 2 years of dialysis
BHT NT HOT HT BHT NT HOT
After 2 or more years of
dialysis
HT HT BHT NT HOT
Hypertensive 1 to 5 yrs.
before dialysis treat-
ment until entry of
treatment
Normotensive 1 to 5 yrs.
before dialysis treat-
ment, but hypertensive
on entry of treatment
Normotensive until entry
of dialysis treatment
11
15
6
3
I
—
1 6 — — 1 8 1
5 8 — 1 1 Ii 1
— 6 — — — 6 —
—
—
—
— 4 3
1 5 3
— 3 1
Abbreviations are: HT, hypertensive; BHT, borderline hypertensive; NT, normotensive; HOT, hypotensive
measured and blood was always taken between 9.00 and 10.00
a.m., that is 10 to 20 hours after the last dialysis treatment.
After 30 minutes of rest, 20 ml venous blood was withdrawn
with the subjects in sitting position and anticoagulated by
mixing 9 ml of blood with 1 ml of 3.2% sodiumcitrate solution.
In addition 5 ml of blood were mixed with 50 d of a solution
containing 190 mg EGTA and 40 mg DTT per ml for determi-
nation of plasma catecholamines.
Platelet membrane preparation and 3H-yohimbine binding
assay was performed as recently described [13]. Briefly, mem-
branes (approximately 50 to 100 sg of protein) were incubated
with 6 to 8 concentrations of 3H-yohimbine (ranging from 0.5 to
10 nmol/liter) at 25°C for 30 minutes in a total volume of 250 p1.
Incubation was terminated by diluting the entire reaction mix-
ture with 10 ml incubation buffer (50 mmol/liter Tris-HC1, 0.5
mmol/liter EDTA adjusted to pH 7.4 with 1.0 mmol/liter HC1)
followed by rapid filtration over Whatman GF/C glass fiber
filters. After drying filters were transferred to vials containing 5
ml of Unisolve (Zinsser, Frankfurt, FRG) as scintillation fluid
and the radioactivity was determined in a Beckman LS 9000
liquid scintillation counter (Beckman Instruments, Fullerton,
California, USA). "Non-specific binding" of 3H-yohimbine was
defined as binding to platelet membranes not displacable by 10
imol/1iter phentolamine. Under these experimental conditions
the intra-individual variation of platelet a2-adrenoceptor num-
ber was less than 15%.
Seventeen patients on maintenance hemodialysis and eight
healthy volunteers participated in the phenylephrine study. The
patients were divided into two age—matched groups: one group
of hypotensive dialysis patients (4 males, 4 females) with
relatively low, interdialytic blood pressure < 110 mm Hg;
blood pressure average 103.3 2.8/72.5 2.3 mm Hg; mean
age 50.0 3.2 [36 to 60] years; duration of hemodialysis
treatment 79.6 12 [34 to 133] months; these patients had very
often hypotensive episodes during dialysis); and one group of
normotensive dialysis patients (8 males, 1 female) with normal
interdialytic blood pressure 135 mm Hg; blood pressure
average 144.2 3.6/88.4 2.0mm Hg; mean age 48.2 3.8 [27
to 56] years; duration of hemodialysis treatment 24 4 [6 to 411
months; blood pressure was relatively stable during dialysis).
There was no difference in the mean body weight of the two
groups. The age—matched control group consisted of four male
and four female volunteers, mean age: 49.3 5.9 (27 to 68)
years; blood pressure average: 132 6/74.8 2.7 mm Hg. The
phenylephrine test was performed always between 8.00 and
10.00 a.m. The subjects remained supine for at least 30 minutes.
Thereafter bolus doses of phenylephrine were injected into the
cubital vein and blood pressure was measured repeatedly by the
auscultatory method (diastolic phase V). Progressively larger
doses of phenylephrine were injected starting with 100 g, until
the systolic blood pressure transiently increased by 20 mm Hg.
Blood pressure was allowed to return to control value before
each successive injection.
To evaluate autonomic function a series of standardized
clinical tests was performed in the same three age—matched
groups. The tests were performed in supine position after one
hour of rest always between 8.00 and 10.00 a.m.
Valsalva—maneuver
Patients were instructed to blow into a mouthpiece connected
to a mercury manometer at a respiratory pressure of 40 mm Hg
for 15 seconds. Heart rate was continuously recorded on an
electrocardiogram throughout the maneuver and for 30 seconds
after the end of the maneuver. The heart rate response to the
Valsalva—maneuver was expressed as the Valsalva ratio [14],
that is, the ratio between maximal bradycardia (longest RR
interval) after strain release and maximal tachycardia (shortest
RR-interval) during the strain period. The mean of two Valsalva
ratios was used for analysis.
Sustained hand—grip test
After instruction on the use of the hand—grip dynamometer
patients gripped the instrument maximally with their hand for a
few seconds. The highest value of three grip contractions was
taken as the maximal voluntary force. Hand—grip was then
maintained at 30% of this value continuously for three minutes.
Blood pressure was measured at the non-exercised arm at rest
and at one minute intervals during hand—grip. Heart rate was
recorded using an electrocardiogram.
Deep breathing
Subjects were instructed to breathe deeply at a rate of 6
breaths/mm. Between the 20th and 50th second of deep breath-
ing each RR-interval was determined from the automatic elec-
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Fig. 1. Correlation between plasma noradrenaline levels and platelet
cr2-adrenoceptor density in 32 patients on maintenance hemodialysis.
Ordinate: platelet a2-adrenoceptor density—determined by Scatchard
analysis [17] of 3H-yohimbine binding—in fmol 3H-yohimbine specifi-
cally bound/mg protein. Abscissa: plasma noradrenaline concentrations
in ng/ml.
trocardiographic tracings. Beat—to—beat variation was calcu-
lated as the standard deviation of the mean instantaneous heart
rate over the 30 second period analyzed.
Plasma noradrenaline levels were assessed by the radioenzy-
matic method of Da Prada and ZUrcher [15] as modified by
Nagel and Schumann [161. Protein was determined by the
Lowry method using bovine serum albumin as standard.
Calculations and statistical evaluations
The experimental data given in text and figures are means
SEM of N experiments. The maximal number of 3H-yohimbine
binding sites in platelet membranes and the equilibrium disso-
ciation constants (Ku) were calculated from plots according to
Scatchard [17]. Linear regression analysis of the data was
performed by the least squares method. Mean arterial blood
pressure (MAP) was calculated according to the equation:
2 x P diast + P systMAP =
3
The significance of differences was estimated by unpaired
Student's t-test. A P value less than 0.05 was considered to be
significant.
U I I — U I I
0 20 40 60 80 100 120 140
Duration of dialysis treatment, months
Fig. 2. Correlation between duration of hemodialysis treatment and
platelet cs2-adrenoceptor density in 32 patients on maintenance hemo-
dialysis. Ordinate: platelet n2-adrenoceptor density-determined by
Scatchard analysis [17] of 3H-yohimbine binding—in fmol H-yohim-
bine specifically bound/mg protein. Abscissa: duration of dialysis
treatment in months.
ent decrease in ct2-adrenoceptor density in platelets of healthy
volunteers [181 platelet a2-adrenoceptor density in the patients
on maintenance hemodialysis was not related to age, but was
significantly inverse correlated to the plasma noradrenaline
levels (Fig. 1). In addition, both platelet a2-adrenoceptor den-
sity and plasma noradrenaline levels were significantly related
to the duration of the hemodialysis treatment: with increasing
duration of treatment platelet aradrenoceptor density de-
creased (Fig. 2), whereas plasma noradrenaline levels increased
(Fig. 3). Moreover, the mean arterial blood—pressure of the
patients was significantly correlated with duration of dialysis
treatment, platelet cx2-adrenoceptor density, and plasma nora-
drenaline levels. Mean arterial blood—pressure decreased with
increasing duration of dialysis treatment (Fig. 4) and increasing
plasma noradrenaline levels (Fig. 5); on the other hand, it was
positively correlated to the density of platelet a2-adreno-
ceptors, that is the higher the density of a2-adrenoceptors, the
higher the mean arterial blood pressure of the patients (Fig. 6).
Changes in a1-adrenoceptor function in patients on
maintenance hemodialysis
In order to find out whether a1-adrenoceptor function might
also be changed in the course of dialysis treatment, the blood
pressure response of healthy volunteers (mean platelet a2-
adrenoceptor density 124 26 (109 to 214) fmol 3H-yohimbine
bound/mg protein, N = 8; mean plasma noradrenaline levels
0.42 0.14 (0.16 to 0.66) ng/ml, N = 8) to i.v. injections of the
selective a1-adrenoceptor agonist phenylephrine was compared
with those in dialysis patients. For this purpose the patients on
maintenance hemodialysis were divided into two age—matched
groups. One group had normal blood pressure (mean platelet
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Results
Changes of platelet a2-adrenoceptor density in patients on
maintenance hemodialysis
In the 32 patients on maintenance hemodialysis the mean
number of a2-adrenoceptors in the platelets, determined by
Scatchard analysis of 3H-yohimbine binding, amounted to 114.3
9.6 (range 25 to 247) fmol 3H-yohimbine specifically bound/mg
protein. In contrast to our recent observation of an age—depend-
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Fig. 3. Correlation between duration of hemodialysis treatment and
plasma noradrena/ine levels in 32 patients on maintenance hemodial-
ysis. Ordinate: plasma noradrenaline concentrations in ng/ml. Abscissa:
duration of dialysis treatment in months.
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Fig. 5. Correlation between mean arterial blood pressure and plasma
noradrenaline levels in 32 patients on maintenance hemodialysis.
Ordinate: plasma noradrenaline concentrations in ng/ml. Abscissa:
mean arterial blood pressure in mm Hg.
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Fig. 4. Correlation between duration of hemodialysis treatment and 150 -
mean arterial blood pressure in 32 patients on maintenance hemodial- '
ysis. Ordinate: mean arterial blood pressure in mm Hg. Abscissa:
duration of dialysis treatment in months.
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co2-adrenoceptor density 135 15.5 [86.7 to 209.7] fmol 3H-
yohimbine bound/mg protein, N 9, mean plasma noradrena-
line levels 0.48 0.04 [0.35 to 0.59] ng/ml) and one group had
relatively low blood—pressure (mean platelet a2-adrenoceptor
density 71.7 16.3 [25 to 102.5] fmol 3H-yohimbine bound/mg
protein, mean plasma noradrenaline levels 0.89 0.13 [0.72 to
1.35] ng/ml, N = 8). Phenylephrine increased the blood pres-
sure in a dose—dependent manner in all three groups (Fig. 7). In
healthy controls and normotensive dialysis patients the dose—
response curves of phenylephrine were nearly superimposable;
in the group of hypotensive dialysis patients, however, the
slope of the curve was significantly reduced. Accordingly, the
S • •
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Mean arterial blood pressure, mm Hg
Fig. 6. Correlation between mean arterial blaod pressure and platelet
a2-adrenoceptor density in 32 patients on maintenance hemodialysis.
Ordinate: platelet o2-adrenoceptor density—determined by Scatchard-
analysis [17] of 3H-yohimbine binding in fmol 3H-yohimbine specifically
bound/mg protein. Abscissa: mean arterial blood pressure in mm Hg.
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Dose of phenyleph rifle, g
Fig. 7. Effects of i.v. injections of phenylephrine on systolic blood
pressure in 8 healthy volunteers (I—D),9 normotensive patients on
maintenance hemodialysis (• •) and 8 hypotensive patients on
maintenance hemodialysis (A—A). Ordinate: Increase in systolic
blood pressure in mm Hg. Abscissa: Dose of phenylephrine in g.
Means SEM. Symbols are: ** P < 0.01, * p < 0.05 vs. normotensive
controls.
EC20-value of phenylephrine (the dose required to increase
systolic blood pressure by 20 mm Hg) was significantly higher
(P < 0.01) in the group of hypotensive dialysis patients (384.5
48 g, N = 8) than in the other two groups (control, 238.3 55
p.g, N = 8; normotensive dialysis patients, 227.6 44 j.tg, N =
9). For all 25 patients there was an inverse relationship between
the EC20-values of phenylephrine and platelet a2-adrenoceptor
density, although it did not reach statistical significance (r =
—0.3235; 0.1 > F> 0.05).
Autonomic tests
During Valsalva—maneuver, changes in heart rate were nearly
identical in normotensive dialysis patients and healthy controls,
(Fig. 8A), whereas in the group of hypotensive dialysis patients
the increase in heart rate during strain as well as the fall in pulse
rate during the release period were significantly diminished
(Fig. 8A). Accordingly the Valsalva—ratio (Fig. 8B) in hypoten-
sive dialysis patients (1.28 0.06, N = 8) was significantly
lower (P < 0.01) than jn normotensive dialysis patients (1.49
0.07, N = 8) and in the control group (1.56 0.08, N = 8).
Sustained hand—grip exercise caused similar increases in sys-
tolic and diastolic blood pressure in all three groups (Fig. 9).
There were no significant differences between the groups. The
same holds true for sustained, hand grip—induced increases in
heart rate (Fig. 9). Similarly, beat—to—beat variation—expressed
as mean standard deviation of the mean instantaneous heart
rate—was in all three groups nearly identical (Fig. 10); in
addition, the well established age—related reduction in beat-
—to—beat variation [19—21] was similar in all three groups (Fig.
10).
Discussion
The role of the sympathetic nervous activity in blood pres-
sure regulation in uremic patients is still poorly understood.
Because of the lack of a direct measurement of sympathetic
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Fig. 8 A. Heart rate before and during the Valsalva-maneuver in 8
healthy volunteers (EJ—D), 8 normotensive patients on rnainte-
nance hemodialysis (• •) and 8 hypotensive patients on mainte-
nance hemodialysis (A—.-----A), Means SEM. B. Valsalva—ratio (the
ratio between the longest RR interval after strain release and the
shortest RR interval during the strain period of the Valsalva-maneuver)
inS healthy volunteers (CON), 8 normotensive patients on maintenance
hemodialysis (NHD) and S hypotensive patients on maintenance hemo-
dialysis (HHD). (*) Mean value of the Valsalva—ratio in the HHD.
patients was significantly lower (P < 0.01) when compared with the
normotensive controls.
activity in humans, determination of plasma noradrenaline
levels has been taken as an index for sympathetic activity. In
patients with mild renal failure normal or slightly increased
noradrenaline levels have been found [22]. In end—stage renal
failure before initiation of hemodialysis treatment, consistently
elevated plasma noradrenaline levels have been reported [23—26],
which were accompanied by blunted cardiovascular responses
to noradrenaline [251. Similarly, in experimental chronic uremia
in the rat plasma noradrenaline levels were elevated and vas-
cular responses to noradrenaline were reduced [101.
Conflicting data have been reported on plasma levels of cate-
A
A
CON NHD HHD
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Fig. 9. Changes in systolic blood pressure, diastolic blood pressure
and heart rate in 8 healthy volunteers (CON), 8 normotensive patients
on maintenance hemodialysis (NHD) and 8 hypoiensive patients on
maintenance hemodialysis (HHD) in response to 3 mm, sustained
hand—grip exercise at 30% of maximal voluntary force. Ordinates:
increase in systolic blood pressure (left panel) and diastolic blood
pressure (middle panel) in mm Hg and in heart rate (right panel) in
beats/mm.
cholamines in patients on maintenance hemodialysis. Canipese et
al [251, Lake et al [27) and Kettner et al [281 found no
differences in plasma noradrenaline levels between patients on
maintenance hemodialysis and normal subjects; on the other
hand, several groups have reported elevated plasma noradren-
aline levels in patients on maintenance hemodialysis [5, 7—9, 29,
30]. The results of the present study may—at least partly—
explain these discrepancies. As shown in Figure 3, the concen-
tration of plasma noradrenaline increased significantly in the
course of hemodialysis treatment. Thus, in patients who were
on dialysis treatment less than two years, plasma nor-
adrenaline levels were not significantly different from those of
an age—matched control group, whereas with increasing dura-
tion of dialysis treatment plasma noradrenaline levels raised to
pathological values. The mechanism underlying this increase in
plasma noradrenaline levels in chronic hemodialysis patients is
not known at present. However, the present results on the
autonomic nervous system function iii the dialysis patients—
obtained by a combination of commonly used non-invasive
tests [reviewed in 31]— may provide a possible explanation. As
shown in Figure 8, in hypotensive dialysis patients increases in
heart rate during the Valsalva—maneuver (a functional index for
the overall integrity of the baroreflex arc) [32] as well as the
Valsalva—ratio [14] was significantly lower than in normotensive
dialysis patients and in healthy controls. On the other hand,
there were no significant differences between normotensive and
hypotensive dialysis patients and the age—matched healthy
controls in blood pressure and heart rate responses to sustained
hand—grip exercise (an index for the efferent sympathetic path-
way), [33] and in beat—to--beat variation during deep breathing
(an index for the parasympathetic pathway) [19]. The results are
compatible with the view that during the course of long—term
hemodialysis treatment the afferent pathway of the baroreflex
arc might be impaired. Such a defect in the baroreflex arc could
well lead to a reflex increase in sympathetic outflow and an
elevation of plasma noradrenaline levels to maintain blood
pressure. Another possibility could be that plasma noradrena-
Mean value: 4 Mean value: —1 Mean value:
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Fig. 10. Beat—to—beat variation during deep breathing, expressed as
mean standard deviation of the mean instantaneous heart rate, in
relation to age in 8 healthy volunteers (control), 8 normotensive
patients on maintenance hemodialysis and 8 hypotensive patients on
maintenance hemodialysis.
line levels might increase reflectorily to an (in chronic uremia
persistently existing) reduced end—organ response to a-adreno-
ceptor stimulation caused by unknown factors (uremic toxins?),
as has been demonstrated in experimental chronic uremia [10)
as well as in uremic man [5, 25, 28].
In the past few years radioligand binding studies have led to
a rapid progress in understanding the molecular pharmacology
of a- and /3-adrenoceptors. It is now apparent that a wide
variety of hormones, drugs, physiological and pathological
conditions may alter adrenoceptor number and, by this, the
sensitivity of tissues to catecholamines [reviewed in 34, 35].
Catecholamines can regulate the concentration of their own
receptors. An increase in catecholamine concentration reduces
the number ("down—regulation"), while reduction in catechol-
amine concentration increases the number of receptors ("up—
regulation") [34, 35]. Thus it might be possible that the decrease
in platelet a2-adrenoceptor density observed in the present
study is caused through homologous down—regulation by the
increased, endogenous noradrenaline levels.
The physiological importance of changes in a2-adrenoceptors
measured in human platelets to changes occuring in other
human (solid) tissues has not been directly established. How-
ever, the properties of a2-adrenoceptors in platelets —assessed
by radioligand binding studies in vitro — are very similar to
those in other peripheral and central tissues [36] including
human cerebral cortex [37]; moreover, Sogabe Hashimoto and
Nakashima [38) have recently demonstrated that the affinities of
a-adrenergic drugs for postsynaptic a2-adrenoceptors in dog
saphenous vein mediating vasoconstriction resemble those in
rat brain and human platelets assessed by 3H-yohimbine bind-
ing. And finally in asympathicotonic orthostatic hypotension
with low plasma noradrenaline levels, platelet a2-adrenoceptor
density was found to be markedly increased; concomitantly an
exaggerated blood pressure response to i.v. injection of the
a1-adrenoceptor agonist phenylephrine was obtained [39]. Tak-
ing these results into account it might be concluded that
changes in platelet a2-adrenoceptors can be taken as repre-
sentative for changes of a2- (and/or a1-) adrenoceptors in other
(solid) tissues, for example, in the vasculature of the human
being.
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Accordingly, in the present study the decrease of a2-adreno-
ceptor density in platelets of patients on maintenance hemodi-
alysis (presumably caused by the increase in plasma noradre-
naline concentrations) might reflect a decrease in vascular
a-adrenoceptor responsiveness. This is, as shown in Figure 7,
indeed the case; in patients, who were for a short period on
dialysis treatment and had only slightly reduced platelet ar
adrenoceptor density, the EC20-value for the blood pressure
increasing effect of phenylephrine was not significantly different
from that in an age—matched, healthy control group; on the
other hand, in patients who were for a rather long time on
dialysis treatment and had low platelet a2-adrenoceptor den-
sity, the slope of the dose—response curve for the blood
pressure increasing effect of phenylephrine was decreased and
the EC20-value was nearly twice as high as in healthy controls.
This clearly indicates a reduced responsiveness of vascular
a1-adrenoceptors to a-adrenergic stimulation. Since postsynap-
tic a1- and a2-adrenoceptors are involved in the maintenance of
peripheral vascular resistance [401 and thus in blood pressure
control, such reduced postsynaptic a-adrenoceptor responsive-
ness might well be one major cause for the development of
hypotension in hemodialysis patients. This hypothesis is sup-
ported by the fact that in the present study the mean arterial
blood pressure of the patients was directly correlated with the
density of platelet a2-adrenoceptors (and hence with the re-
sponsiveness of vascular a1- and a2-adrenoceptors). Thus,
patients, who were for a long time on hemodialysis treatment,
exhibit high plasma noradrenaline levels, low platelet a2-adre-
noceptor densities, low blood pressure responses to phenyl-
ephrine, and arterial hypotension. Similar results have been
recently obtained by Botey et al [51 and Brech, Piazolo and
Buerkle [30], who observed that in hypotensive, but not in
normotensive hemodialysis patients, plasma noradrenaline lev-
els were significantly higher and increments in mean arterial
blood pressure during noradrenaline infusion were significantly
lower than in their normotensive counterparts.
In conclusion, the present results are in favor of the idea that
in patients on maintenance hemodialysis blood pressure might
be regulated by an interplay of endogenous noradrenaline
concentrations, vascular response to a-adrenoceptor stimula-
tion and the duration of dialysis treatment. In the course of
long—term dialysis treatment plasma noradrenaline levels in-
crease, platelet a2-adrenoceptors (reflecting obviously vascular
sensitivity to a-adrenoceptor stimulation) decrease, and hence
mean arterial blood pressure decreases. One possible cause for
these alterations might be that plasma noradrenaline levels
increase reflectorily to chronic uremia (persistently) existing,
end—organ resistance to a-adrenoceptor stimulation caused by
unknown factors (uremic toxins); this increase might initially
prevent hypotension, but in the course of long—term dialysis
treatment leads finally to a down—regulation of a-adrenoceptors
and thus to arterial hypotension. A more likely explanation
could be, however, that the primary cause of these alterations
might be a dysfunction of the afferent limb of the baroreflex arc
that leads to an enhanced sympathetic outflow and an increase
in plasma noradrenaline levels. These increased noradrenaline
levels, which initially may maintain blood pressure, induce
during long—term dialysis treatment a down—regulation of (vas-
cular) a-adrenoceptors leading finally to arterial hypotension.
Both hypotheses imply that the duration of dialysis treatment
seems to play an important role: in the course of long—term
dialysis treatment the sensitivity of the vasculature to a-
adrenoceptor stimulation is declining (obviously due to a reduc-
tion in the density of functional a-adrenoceptors), which might
be one of the reasons for arterial hypotension in patients on
long—term hemodialysis treatment.
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